Key Points
- Insider sale: Kristen Cunningham sold 8,901 Lifevantage shares for approximately $55,008, reducing her position by 6.9% to 120,162 shares. She also sold 100 shares in a separate transaction the previous week.
- Financial performance: Lifevantage reported quarterly earnings of $0.11 per share, below the $0.12 consensus estimate, while revenue of $42.38 million also missed expectations of $44.00 million.
- Market outlook and dividend: Shares recently traded around $6.25, and analysts maintain a consensus “Hold” rating with a $5.50 price target. The company declared a quarterly dividend of $0.05 per share, representing a 3.2% annualized yield.
Lifevantage Corporation (NASDAQ:LFVN - Get Free Report) insider Kristen Cunningham sold 8,901 shares of the company's stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $6.18, for a total value of $55,008.18. Following the completion of the sale, the insider owned 120,162 shares in the company, valued at $742,601.16. The trade was a 6.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Kristen Cunningham also recently made the following trade(s):
- On Friday, September 11th, Kristen Cunningham sold 100 shares of Lifevantage stock. The stock was sold at an average price of $6.41, for a total value of $641.00.
Lifevantage Trading Up 1.3%
Shares of LFVN stock opened at $6.25 on Tuesday. Lifevantage Corporation has a twelve month low of $3.90 and a twelve month high of $11.71. The stock has a market cap of $78.31 million, a P/E ratio of 15.62 and a beta of 0.73. The stock has a 50 day moving average of $6.41 and a 200 day moving average of $5.95.
Lifevantage (NASDAQ:LFVN - Get Free Report) last released its quarterly earnings data on Thursday, August 27th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.01). The company had revenue of $42.38 million during the quarter, compared to analysts' expectations of $44.00 million. Lifevantage had a return on equity of 21.56% and a net margin of 2.78%. On average, research analysts predict that Lifevantage Corporation will post 0.39 earnings per share for the current fiscal year.
Lifevantage Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Tuesday, September 1st will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $0.20 dividend on an annualized basis and a yield of 3.2%. Lifevantage's dividend payout ratio is 50.00%.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on LFVN shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Lifevantage in a report on Friday, August 21st. Lake Street Capital increased their target price on shares of Lifevantage from $5.00 to $6.00 and gave the stock a "hold" rating in a research note on Friday, August 28th. Two analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $5.50.
Get Our Latest Analysis on LFVN
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in LFVN. DGS Capital Management LLC acquired a new stake in Lifevantage in the 1st quarter valued at $44,000. Hsbc Holdings PLC purchased a new stake in Lifevantage in the 1st quarter worth $51,000. Aristides Capital LLC acquired a new position in Lifevantage during the fourth quarter worth $76,000. Bank of New York Mellon Corp acquired a new position in Lifevantage during the second quarter worth $78,000. Finally, Bank of America Corp DE lifted its holdings in Lifevantage by 24.3% during the first quarter. Bank of America Corp DE now owns 23,445 shares of the company's stock valued at $101,000 after purchasing an additional 4,586 shares in the last quarter. Hedge funds and other institutional investors own 35.32% of the company's stock.
Lifevantage Company Profile
(
Get Free Report)
LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company's flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.
Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
